Clinical Trial Update: Effect of Ruxolitinib on Tumor Infiltrating Myeloid Cells [NA]

View source ↗

Summary

A clinical trial evaluating the effect of ruxolitinib on tumor-infiltrating myeloid cells in prostate cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Ruxolitinib (ruxolitinib)

Snippet

Sponsor: Oncology Institute of Southern Switzerland | Conditions: Prostate Cancer | NA | Status: WITHDRAWN